Dr. Romanenko received her Ph.D. from Novosibirsk State University and subsequently completed specialized training at the State Research Center of Virology and Biotechnology "VECTOR," where she gained expertise in working with viruses in compliance with biosafety regulations, including adenovirus amplification and both in vitro and in vivo experimental techniques.

From 2011 to 2020, Dr. Romanenko contributed to the development of novel oncolytic adenoviral vectors based on adenovirus serotypes 5 and 6 at Novosibirsk State University in the laboratory of Prof. Netesov. During this period, her group developed an innovative method for adenoviral genome modification, which enabled the generation of a triple-recombinant Ad6-based oncolytic vector with enhanced tumor specificity and antitumor efficacy across multiple cancer types. In addition, the group established the first hamster model of cholangiocarcinoma and used it to demonstrate the therapeutic efficacy of the Ad6-based oncolytic vector in vivo.

Since joining the Department of Surgery at the University of Minnesota in August 2020, Dr. Romanenko's research has focused on the development of next-generation oncolytic adenoviral vectors based on multiple adenovirus serotypes using modern molecular and translational approaches. Her recent work includes comprehensive in vitro and in vivo studies investigating the biodistribution, replication, and toxicity profiles of adenovirus-based vectors in pigs, as well as studies of adenovirus interactions with porcine blood cells and coagulation factors. These findings have been directly compared with corresponding human cells and factors to evaluate the translational relevance of the porcine model for adenovirus research and clinical development.